Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M3\RVGZ2dmO2aX;uJGF{e2G7 NH3yOWsxNjFvM{Cg{txO MXy0PEBp Mnu5bY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> MlTYNlY2OTNzN{K=
H460 Mnv4SpVv[3Srb36gRZN{[Xl? NFuzcG4xNjFvM{Cg{txO M2n2eFQ5KGh? MVHpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NIr1SVAzPjVzM{G3Ni=>
HKESC-2 NWjDU4g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqyNOKh|ryP M1fRXlQ5yqCqwrC= NHS5SGh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? MV6yOlQ4PDZ7Mx?=
CaES-17 M1[zR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XSS|IxyqEQvF2= M1Xkc|Q5yqCqwrC= MWfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> MVSyOlQ4PDZ7Mx?=
HKESC-2 M2PaTmFxd3C2b4Ppd{BCe3OjeR?= MWWyNOKh|ryP NGTzOII1QMLiaNMg MYPy[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz NX75c2pjOjZ2N{S2PVM>
CaES-17 MmLWRZBweHSxc3nzJGF{e2G7 MWeyNOKh|ryP NH36UYo1QMLiaNMg MVjy[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz NWHmNHcxOjZ2N{S2PVM>
A549 NWfzVVRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LlOVUuOTZyIN88US=> NU\OVWptPDkEoHlCpC=> M{jRU2ROW09? NWDDSpZHUUN3ME2xOlMvPCEQvF2= M4jJU|I3PDZ2NkSz
HCC827 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T4PFUuOTZyIN88US=> NIjVZo41QMLiaNMg M3LDNWROW09? MVrJR|UxRTZ7LkKg{txO NGP3[WIzPjR4NE[0Ny=>
A549 Mle4RZBweHSxc3nzJGF{e2G7 MnvuPFAhyrWP Mnr4OFjDqGkEoB?= MVrEUXNQ MmLnbY5lfWOnczDhdI9xfG:|aYO= M3fsVlI3PDZ2NkSz
HCC827 NUfkVVYySXCxcITvd4l{KEG|c3H5 MVS4NEDDvU1? NYnVUHF{PDkEoHlCpC=> MXjEUXNQ NUXJcHdwcW6mdXPld{BieG:ydH;zbZM> M3[xT|I3PDZ2NkSz
SGC-7901/DDP NV\Zc|BOTnWwY4Tpc44hSXO|YYm= M4DvSFExyqEEtV2= Mn\aNlQhcA>? M3TWUolvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> M37BWVI3PDB5NkWz
SGC-7901  Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmyOOKhcMLi MYTJR|UxRTFzNT6wPEDPxE1? MkP6NlY1ODd4NUO=
SGC-7901/DDP NGj6VpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H6b|I1yqCqwrC= M171S2lEPTB;M{WuOFUh|ryP NEjUNG0zPjRyN{[1Ny=>
SGC-7901/DDP MWDBdI9xfG:|aYOgRZN{[Xl? MUWxNOKhyrWP MmPVNlQhcA>? MofMbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> NIjkd5gzPjRyN{[1Ny=>
SGC-7901/DDP M1jrNWZ2dmO2aX;uJGF{e2G7 M1W3eFExyqEEtV2= NGTmTm0zPCCq NX2yZVZKcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= MYqyOlQxPzZ3Mx?=
SGC-7901/DDP NVzQTmNCTnWwY4Tpc44hSXO|YYm= MkG1NVDDqML3TR?= MkTkNlQhcA>? MV;jZZV{\XNiYTDtZZJs\WRiZHXjdoVie2ViaX6geIhmKGyndnXsJI9nKEKlbD2yJJBzd3SnaX6= MViyOlQxPzZ3Mx?=
H357 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHBcVI{Py53L{GwJO69VQ>? NHW1S5U1QCCq MnjtSG1UVw>? MmTXbY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=> NUnD[4NqOjZyMEm4O|Q>
TAF M1jldmZ2dmO2aX;uJGF{e2G7 MWSxNOKhyrWP MVW3JIQ> NVWwZ|c5[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= NVvtfGFsOjV7OEexNlc>
TAF NGPUO4ZHfW6ldHnvckBCe3OjeR?= MkniNVDDqML3TR?= NUfBc4lZOzBvMUKwJI1qdg>? MlSwdI9wemy7IHHm[oVkfHNiZFHreEBxcG:|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n MVKyOVk5PzF{Nx?=
TAF Mn[xSpVv[3Srb36gRZN{[Xl? NVu0WZg1OTEEoNM1US=> M3TWV|Q5KGh? NHPmSWhqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= Mmn5NlU6QDdzMke=
PANC-1 M2\JfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;kVFIzOC94MD:xNFAh|ryP NXf1WnJIOjRxNEivO|IhcA>? MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mli1NlU6PzNyNkK=
PANC-1 NHnSbmZHfW6ldHnvckBCe3OjeR?= MUmyNE83OC9zMECg{txO MXyyOEBp NITze3NifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M{Hq[lI2QTd|ME[y
HeLa  NH7MO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSyNOKh|ryPwrC= MY[yOOKhcA>? M2LxNoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w NV\YfYV3OjV5N{C0NlM>
SACC-83 M1e1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLMdmEzOMLizszNxsA> MluwNlTDqGh? MnXQ[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? M{HhR|I2PzdyNEKz
HeLa  Mlu3RZBweHSxc3nzJGF{e2G7 NHfodpYzOMLizszNxsA> NVLDR5hXOjUEoHi= MUTlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz NFfuPIUzPTd5MESyNy=>
SACC-83 NVzJcWU4SXCxcITvd4l{KEG|c3H5 MUKyNOKh|ryPwrC= NIjzc4IzPMLiaB?= NGfjcItmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ NX3tUGd[OjV5N{C0NlM>
HeLa  NWLDXIhHTnWwY4Tpc44hSXO|YYm= NEDwOJEzOC92MD:4NEDPxE1? M2XVflI1yqCq M1vlTJVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV MlXWNlU4PzB2MkO=
SACC-83 MmrBSpVv[3Srb36gRZN{[Xl? NXO4N21ZOjBxNECvPFAh|ryP NUe0e|ZSOjUEoHi= NVvpW5lIfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? MVGyOVc4ODR{Mx?=
HLCZ01 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDQfppPOOLCk{[wxsDDvU1? NVPUfXlmPDhiaB?= MYLEUXNQ MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHT4cJAzPTd{NEi5PS=>
HLCZ01 NVnzN4NoTnWwY4Tpc44hSXO|YYm= NHq1XmI1OMLizszN M1;sVFI1KGh? NEPGVFhFVVOR MkLTbY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=> NVHSSmRtOjV5MkS4PVk>
HLCZ01 NYfIeI4zSXCxcITvd4l{KEG|c3H5 M3;KXlQxyqEQvF2= MWCyOEBp MlfoSG1UVw>? NYXodJdQ\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z NFjxPXEzPTd{NEi5PS=>
HLCZ01 NH\nUGdHfW6ldHnvckBCe3OjeR?= NWTSeVREPDEEoN88US=> Mmn5NlQhcA>? M{LUbGROW09? MVLpcoNz\WG|ZYOgWHJCUUxiZYjwdoV{e2mxbjDjc41jcW6nZDD3bZRpKEmwdHXy[oVzd25vzsG= NXj5THc3OjV5MkS4PVk>
MGC803 NX\kOFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmwMVYxKM7:TR?= NH3UeGQ4OiCq NXjhTmR5UUN3ME20O{4zPeLCidMx5qCKPi52MzFOwG0> Mn[wNlU4ODF|N{i=
SGC7901 NVnYTG9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zkOVAuPjBizszN NYXCcnBWPzJiaB?= NVL2cWk1UUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> NWLuUVNUOjV5MEGzO|g>
MGC803 Ml\RSpVv[3Srb36gRZN{[Xl? NFXOXo01OMLizszN NFzGfHE5NzF4L{K0JIg> M1\MZpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NI\IfJQzPTdyMUO3PC=>
SGC7901 M2fCc2Z2dmO2aX;uJGF{e2G7 NGLPV3g1OMLizszN NXmxSopXQC9zNj:yOEBp MmDGeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u NYTBVm1KOjV5MEGzO|g>
MCF-7  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCxM|ExKM7:TR?= MmTlO|IhcA>? M33D[WROW09? Ml35[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NUjDbZZ3OjV4Nke1NVA>
MDA-MB-231  NX31fJlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD1bFAyNzFyIN88US=> MYC3NkBp NYj6THhPTE2VTx?= M4n4eoVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w Ml71NlU3Pjd3MUC=
MDA-MB-231 MVvGeY5kfGmxbjDBd5NigQ>? M{nERVAuPDBiwsXN NY\jTGlvPC1{NDDo MW\pcoNz\WG|ZYOgR29ZNTJicILveIVqdiCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NHjodWUzPTV6N{OyPS=>
MCF-7 NHizXHFHfW6ldHnvckBCe3OjeR?= MWOwMVQxKML3TR?= M4e0elQuOjRiaB?= M1L3dYVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? M3f3VlI2PTh5M{K5
MCF7-MX  MV7GeY5kfGmxbjDBd5NigQ>? MV6wMVQxKML3TR?= MnT1OE0zPCCq M1PCOoVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? MoLTNlU2QDd|Mkm=
MDA-MB-231 MkXxSpVv[3Srb36gRZN{[Xl? MkPTNE01OCEEtV2= NX\tSnJyPC1{NDDo MVTzeIlufWyjdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGFDS0d{IIXwJJRwKDRwMkegeIlu\XNidH:gZ49vfHKxbDDs[ZZmdCCkeTCxNkBpyqB? Mlj2NlU2QDd|Mkm=
A2780 NICzU2xHfW6ldHnvckBCe3OjeR?= M1HvWVUwOTBxMUWg{txO M4\2ZlQ5KGh? NX;nS4E1\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3XvbVI2PDJ2OEm4
SKOV3  NX3XOpRCTnWwY4Tpc44hSXO|YYm= NE\BRVc2NzFyL{G1JO69VQ>? NEXzVoo1QCCq NFXKe4pl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlzWNlU1OjR6OUi=
A2780 M3fVdGZ2dmO2aX;uJGF{e2G7 MmHjOU8yOC9zNTFOwG0> MmW5OFghcA>? MVXlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv NEjXdXczPTR{NEi5PC=>
SKOV3  Mm\ySpVv[3Srb36gRZN{[Xl? M4PBdVUwOTBxMUWg{txO M{\xVVQ5KGh? MUflcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv M1vOVFI2PDJ2OEm4
A2780 NWXZbpR7TnWwY4Tpc44hSXO|YYm= MmHVOU8yOC9zNTFOwG0> Ml;2OFghcA>? Mm\y[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw M4e4dFI2PDJ2OEm4
SKOV3  MVHGeY5kfGmxbjDBd5NigQ>? MXW1M|ExNzF3IN88US=> NF3RPXk1QCCq M3LIVYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= M4LyfVI2PDJ2OEm4
A2780 MVfGeY5kfGmxbjDBd5NigQ>? MnjROU8yOC9zNTFOwG0> NEDVRmwyKGh? MUDpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEHOeY4zPTR{NEi5PC=>
SKOV3  MknhSpVv[3Srb36gRZN{[Xl? MmXlOU8yOC9zNTFOwG0> MV2xJIg> NWXuUplucW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWiyOVQzPDh7OB?=
HCT-15 Mne5SpVv[3Srb36gRZN{[Xl? NEHUN5EyOC13MDFOwG0> NHHjfmU3NTN4IHi= NFzsTYpqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NIrnNo4zPTJzOECyPC=>
HT-29  MlTSSpVv[3Srb36gRZN{[Xl? MUSxNE02OCEQvF2= NXfhcGZlPi1|NjDo NUjiRYZrcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MWCyOVIyQDB{OB?=
HSC3  NXO1S4d5S2WubDDWbYFjcWyrdImgRZN{[Xl? NFPYR2kx6oDVNECg{txO NVT5c5hNPDhiaB?= MUjJR|UxRTJ3LkZCtVEvPzhyIN88US=> MVKyOVE6QDd6OR?=
HSC3  MYXBdI9xfG:|aYOgRZN{[Xl? NFW4SFMzPSEQvF2= M3izNFQ5KGh? NUfNcYpncW6mdXPld{BieG:ydH;zbZM> MUGyOVE6QDd6OR?=
HSC3  M4e5dmZ2dmO2aX;uJGF{e2G7 MUCyOUDPxE1? MVO0PEBp MoSz[ZhpcWKrdIOgd4lodmmoaXPhcpRtgSC{ZXT1Z4VlKG2rZ4LheIlwdiClb33ibY5m\CC5aYToJGNGXA>? NF61bpAzPTF7OEe4PS=>
HSC3  M3zlOmZ2dmO2aX;uJGF{e2G7 NHe4VGYzPSEQvF2= MlvHOFghcA>? M1rmR4lvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> M32yPVI2OTl6N{i5
HSC3  M4PETWZ2dmO2aX;uJGF{e2G7 MV6yOUDPxE1? NWftNppHPzJiaB?= NIDBfnll\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> MUOyOVE6QDd6OR?=
201T  MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq5TIY4OiCq MXHEUXNQ M4\5cmlEPTB;NEiuOkDDvU1? MY[yOVA2Pzl2MR?=
273T M3XuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljrO|IhcA>? MWnEUXNQ NUnhRoJ1UUN3ME24NE42KML3TR?= NYmwUmFVOjVyNUe5OFE>
Hep-2 M{[xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVizNE82OC9zMECg{txO Ml7YNVIwOjRxM{[vOFghcA>? M{P2cGROW09? NGr6SopqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mn;YNlQ6QTh3NkS=
Hep-2 NUnH[GN3SXCxcITvd4l{KEG|c3H5 M2XxPVUxKM7:TR?= Ml7TNE01QCCq MXfEUXNQ MV3pcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MVuyOFk6QDV4NB?=
Hep-2 MnnmSpVv[3Srb36gRZN{[Xl? NF3JOow2OCEQvF2= MY[wMVQ5KGh? M3\EPWROW09? MUPy[YR2[2W|IITo[UB1\WyxbXXyZZNmKGGldHn2bZR6KGe{YXT1ZYxtgQ>? NXK4PFF5OjR7OUi1OlQ>
Hep-2 MXTGeY5kfGmxbjDBd5NigQ>? MnfwOVAh|ryP M3\hXVAuPDhiaB?= NHXtboRFVVOR NVTsb3ZF\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? NVPsZllpOjR7OUi1OlQ>
SGC-7901 NGr5PWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL1NVAwPTBxMUCwJO69VQ>? M2jRbVI1NzR6L{eyJIg> MUnEUXNQ MoCybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEXvZZEzPDl7Mkm1PC=>
MKN-45 M2[5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxNE82OC9zMECg{txO MnPHNlQwPDhxN{KgbC=> Mlq1SG1UVw>? MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWOyOFk6Ojl3OB?=
SGC-7901 M{fufmZ2dmO2aX;uJGF{e2G7 MYCxNE82OC9zMECg{txO NIn5RlE1QCCq MUXEUXNQ NGnndlRld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MlfoNlQ6QTJ7NUi=
MKN-45 MXXGeY5kfGmxbjDBd5NigQ>? NY\TZYFZOTBxNUCvNVAxKM7:TR?= MWi0PEBp M1G1emROW09? MkG4[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NFT0TYYzPDl7Mkm1PC=>
C666-1 M3u1XmN6fG:2b4jpZ4l1gSCDc4PhfS=> M1O0PFIxNThyIN88US=> MkXhNlQhcA>? M2TTSIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NEfhcIgzPDh3NEizPC=>
CNE-1 NEDHO3lEgXSxdH;4bYNqfHliQYPzZZk> NVSxSo5qOjBvOECg{txO M2f3c|I1KGh? M3H5VYRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> M2SxV|I1QDV2OEO4
CNE-2 M3rCcGN6fG:2b4jpZ4l1gSCDc4PhfS=> MXSyNE05OCEQvF2= MX[yOEBp MYXk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NFHMOoUzPDh3NEizPC=>
C666-1 NVHubXR4S3m2b4TvfIlkcXS7IFHzd4F6 NUnBVJNOPjBizszN MnzEO{Bl NV3Fdo9P\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> M33vdVI1QDV2OEO4
CNE-1 NIjoN|hEgXSxdH;4bYNqfHliQYPzZZk> NGnlcVM3OCEQvF2= NYG4R2JxPyCm NGPlS5RmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> NFm0XWEzPDh3NEizPC=>
SNU-1041 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSwMVQxKM7:TR?= MYq0PEBp NY\wTINTcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NX2yW3UxOjR4OUK3NFM>
SNU-1041 MmXUSpVv[3Srb36gRZN{[Xl? Ml7ENlAwOzBizszN MojqOEBp NXrDfnF[cW6mdXPld{BmgHC{ZYPzbY9vKG:owrDDTG9RNCCJUmC3POKh[W6mwrDYRnAyyqCjdDD0bIUhWk6DIHzleoVtyqB? NHTaZ2gzPDZ7MkewNy=>
SNU-1041 M1X4TmZ2dmO2aX;uJGF{e2G7 NFyzboMxNTRyIN88US=> M4jneVQhcA>? MkPIeZAuemWpdXzheIV{KEOKT2FCpIFnfGW{IITy[YF1dWWwdDD3bZRpKGirZ3igZ49v[2WwdILheIlwdnN? M3fLT|I1Pjl{N{Cz
SGC-7901 NIHLbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiwUmU2OC1zMkWg{txO M2T4[lI1NzR6L{eyJIg> NITJSY9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NYLLeHl7OjR4N{[zPVQ>
SGC-7901 NXfHWFF[SXCxcITvd4l{KEG|c3H5 NHT3eWYyODBizszN M1;GR|czKGh? NInrb2FqdmS3Y3XzJIFxd3C2b4Ppdy=> M1LnSFI1Pjd4M{m0
SGC-7901 M2jOOGZ2dmO2aX;uJGF{e2G7 MWi3OU8yODBxMUK1JO69VQ>? Mn2zNlQwPDhxN{KgbC=> MXzpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?= MXOyOFY4PjN7NB?=
LMeC  M1PBNGZ2dmO2aX;uJGF{e2G7 NFjGOlkzOC93MDFOwG0> NEDlVIU1QCCq MYrk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJicILveIVqdg>? M2nZflI1PjV4N{S2
CMeC-1 NFrkW2dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Moi4NlAwPTBizszN M3;XWFQ5KGh? NGHuVGtqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX3XUVNQOjR4NU[3OFY>
LMeC MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4mw[VIxNzVyIN88US=> MVG0PEBp NXPqT5N4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MViyOFY2Pjd2Nh?=
CMeC-1 MlvDSpVv[3Srb36gRZN{[Xl? Mlv6NlAwPTBizszN MmnFOFghcA>? NUHhfldGcW6mdXPld{BIOS2VIHHydoV{fA>? M33DXVI1PjV4N{S2
LMeC M{\Dd2Z2dmO2aX;uJGF{e2G7 NFTJXWQzOC93MDFOwG0> M1joWlQ5KGh? MUPpcoR2[2W|IFexMXMh[XK{ZYP0 NHHSRpIzPDZ3Nke0Oi=>
CMeC-1 M4LPeGZ2dmO2aX;uJGF{e2G7 M3LncFIxNzVyIN88US=> MkXjOFghcA>? NF3EZY9l\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MW[yOFY2Pjd2Nh?=
LMeC Ml;6SpVv[3Srb36gRZN{[Xl? M{faXFIxNzVyIN88US=> NVS3NZh{PDhiaB?= MXLk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYL3TXVxOjR4NU[3OFY>
CMeC-1 NF3ycW5HfW6ldHnvckBCe3OjeR?= MlTUNlAwPTBizszN M3jWZlQ5KGh? M3rBNYlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> M3fFNlI1PjV4N{S2
LMeC M1\JRmZ2dmO2aX;uJGF{e2G7 MWqyNE82OCEQvF2= NWPVeo1sPDhiaB?= NGT4[lhqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v NHP6V|UzPDZ3Nke0Oi=>
OVCAR-3 NXXwe|A1S2WubDDWbYFjcWyrdImgRZN{[Xl? MnHCNVAhyrWP NH;reWEyKGh? Mlmx[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> M{K5U|I1PTJyMkK3
OVCAR-3 M1rFSmFxd3C2b4Ppd{BCe3OjeR?= MoC1NVAhyrWP M{i5VFEhcA>? NVuzR3N7eHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li Mme4NlQ2OjB{Mke=
OVCAR-3 NUPvVJhSTnWwY4Tpc44hSXO|YYm= MY[xNEDDvU1? NVvIc3dlOSCq NYG0bZEy\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> M3\wZlI1PTJyMkK3
OVCAR-3 NH;jeWRHfW6ldHnvckBCe3OjeR?= NV\LdoR[OTBiwsXN MX[xJIg> NU\TcZMz\G:5bj3y[Yd2dGG2ZYOgUmYu|rqEIHHjeIl3[XSrb36gbY5lfWOnZDDifUBx[WOuaYThfIVt MVKyOFUzODJ{Nx?=
OVCAR-3 NVnoU2dHTnWwY4Tpc44hSXO|YYm= MWGxNEDDvU1? NUHNWJpHOSCq NGTDU|dqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NXn1UmtuOjR3MkCyNlc>
CF33 MkPESpVv[3Srb36gRZN{[Xl? MX[xNFAh|ryP NULoRmptOjRiaB?= MX3pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIFPPXE0zKHC{b4TlbY4h\XiycnXzd4lwdg>? NXPXe3dSOjR3MEO3PFI>
CF33 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF62RpQyOC1zMECg{txO NXH5NJJ1OC12IHS= MoHZbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NU\MbYFbOjR3MEO3PFI>
CF33 MlHQSpVv[3Srb36gRZN{[Xl? MmjGNVAuOTByIN88US=> MYe0MVI1KGh? NF\WZ|Jl\WO{ZXHz[ZMh[2WubIOgbY4hfGinIGOgdIhie2ViYX7kJIlv[3KnYYPld{Bk\WyuczDpckBIOC:JMTDhdpJme3R? NX[4bItEOjR3MEO3PFI>
LNCaP NEjGUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\vb20zNzVxMUCg{txO MkjEPVYhcA>? NYLTb5o{cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NVTzPJNwOjR{OU[5O|g>
LNCaP NVX5ZXBVSXCxcITvd4l{KEG|c3H5 NUSzTJJyOi93L{GwJO69VQ>? M3fpb|k3KGh? NXnDWJVxcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> M3;FXlI1Ojl4OUe4
PC-3  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C2dlAuPTBizszN NWjDNmlJPDkkgJno MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXeyOFEzPzh6Mh?=
PC-3  MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHrjOlMxNTFyMDFOwG0> NUDCboptPzJiaB?= MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVfjXWJOOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID